A healthy endothelium is covered by a layer of endothelial glycocalyx, which functions to maintain the endothelial lining. As a woven structure, the endothelial glycocalyx extends over the luminal surface of the endothelium. Endothelial dysfunction is hypothesized to contribute to the incidence of DIC significantly. Endothelium activation and endothelium damage are the initial manifestations of coagulopathy in sepsis. In this study, we investigated the relationship between the levels of endothelial glycocalyx damage biomarkers (syndecan-1) and endothelial damage biomarkers (PAI-1, Thrombomodulin, and ADAMTS13) and the incidence of DIC in sepsis. To analyze the relationship between glycocalyx and endothelial damage with the incidence of DIC and predictor markers of DIC incidence in sepsis patients. From October to December 2022, an analytic observational study with a cross-sectional design was conducted at Dr. Wahidin Sudirohusodo Hospital and Hasanuddin University Hospital Makassar. The research participants were sepsis patients who met the inclusion and exclusion criteria. The statistical test utilized SPSS version 25 with the Kolmogorov-Smirnov test for data normality, the bivariate test utilized the unpaired t-test, and the multivariate analysis employed multiple logistic regression tests and examined the Odds Ratio value. The statistical test results were significant if the p-value < 0.05. This study included 55 patients diagnosed with sepsis, with a distribution of 29 men and 26 women. The results showed no relationship between syndecan-1, PAI-1, and thrombomodulin levels and the incidence of DIC in septic patients (p=0.480,0.122, 0.688). There is a relationship between ADAMTS13 levels and the incidence of DIC in septic patients (p=0.024). Using multiple logistic regression tests, the ADAMTS13 biomarker is a biomarker that can be used as a screening biomarker for DIC events in sepsis patients (OR=0.889, CI 95% =0.802-0.986). There is a relationship between endothelial damage with the ADAMTS13 biomarker and DIC in sepsis, and the ADAMTS13 biomarker can be used as a screening tool for DIC in sepsis.